Zacks: Brokerages Anticipate Iovance Biotherapeutics Inc (NASDAQ:IOVA) to Announce -$0.42 Earnings Per Share
Equities research analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to report earnings of ($0.42) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Iovance Biotherapeutics’ earnings, with estimates ranging from ($0.45) to ($0.40). Iovance Biotherapeutics posted earnings of ($0.27) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 55.6%. The firm is expected to issue its next quarterly earnings report on Wednesday, February 26th.
On average, analysts expect that Iovance Biotherapeutics will report full year earnings of ($1.50) per share for the current fiscal year, with EPS estimates ranging from ($1.53) to ($1.47). For the next financial year, analysts anticipate that the company will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.32) to ($0.61). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.01).
A number of institutional investors have recently bought and sold shares of the business. Coastal Investment Advisors Inc. increased its stake in Iovance Biotherapeutics by 2.9% during the 3rd quarter. Coastal Investment Advisors Inc. now owns 29,390 shares of the biotechnology company’s stock worth $534,000 after acquiring an additional 815 shares during the period. Strs Ohio increased its stake in Iovance Biotherapeutics by 0.7% during the 3rd quarter. Strs Ohio now owns 127,800 shares of the biotechnology company’s stock worth $2,325,000 after acquiring an additional 900 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in Iovance Biotherapeutics by 14.9% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,700 shares of the biotechnology company’s stock worth $189,000 after acquiring an additional 1,000 shares during the period. Tower Research Capital LLC TRC bought a new position in Iovance Biotherapeutics during the 2nd quarter worth $29,000. Finally, Edge Wealth Management LLC increased its stake in Iovance Biotherapeutics by 20.2% during the 2nd quarter. Edge Wealth Management LLC now owns 8,414 shares of the biotechnology company’s stock worth $207,000 after acquiring an additional 1,414 shares during the period. Hedge funds and other institutional investors own 97.24% of the company’s stock.
NASDAQ:IOVA traded down $0.97 during mid-day trading on Thursday, hitting $22.90. 1,359,500 shares of the stock were exchanged, compared to its average volume of 1,411,188. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of -18.03 and a beta of 1.96. The firm’s 50-day simple moving average is $19.93 and its 200 day simple moving average is $19.83. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.61 and a current ratio of 10.61. Iovance Biotherapeutics has a fifty-two week low of $7.26 and a fifty-two week high of $26.59.
Iovance Biotherapeutics Company Profile
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
See Also: Arbitrage
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.